Rocket Pharmaceuticals Reports Q1 2026 Net Loss of $47.6M

Rocket Pharmaceuticals (RCKT) reported a net loss of $47.6 million for the first quarter of 2026, driven by reduced R&D and G&A expenses following workforce realignment. The company extended its cash runway to Q2 2028 after selling a Priority Review Voucher for $180 million.

By Maham Fatima Mon, May 18, 2026 at 7:50 AM GMT+3 2 min read · Yahoo Finance · May 18, 2026, 04:50 UTC

Rocket Pharmaceuticals Reports Q1 2026 Net Loss of $47.6M

Tickers: $RCKT

Topics: biotechnology clinical trials rare diseases

Read the full article at Yahoo Finance

More World news

Analyst Ming-Chi Kuo Suggests Nvidia CEO Resignation May Have Limited Near-Term Stock Impact Seeking Alpha · November 12, 2026, 16:53 UTC
Solo Brands Lowers Net Sales Outlook While Projecting 2026 Adjusted EBITDA Growth Seeking Alpha · November 12, 2026, 16:50 UTC
EyePoint Pharmaceuticals Announces Strategic Shift to DURAVYU DME Following Phase III Wet AMD Trial Failures Seeking Alpha · November 12, 2026, 16:50 UTC
Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC